15028 results for "cancer studies using rna-seq"

in 19.64 milliseconds.

• Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases

  Characterizing transcriptommic profiles of the two main histopathological growth patterns in liver metastases in patients with breast cancer.

  Study EGAS50000000225

• Whole exome sequence in EGFR-TKI resistant non-small cell lung cancer

  Whole exome analysis to clear molecular basis and mutation spectrum in EGFR-TKI resistant non-small cell lung cancer

  Study JGAS000102

• OCCAMS_Oesophageal Cancer Organoids_1

  ***THIS DATA CAN ONLY BE USED FOR NON-COMMERCIAL CANCER RESEARCH*** Sequencing of organoid cell lines derived from oesophageal tumour sections taken from patients diagnosed with primary oesophageal cancer who underwent tumour resection surgery.

  Dataset EGAD00001001889

• Cancer_Cell_Line_Exome_Sequencing_

  Genomic characterisation of a large series of cancer cell lines.

  Study EGAS00001000978

• Somatic_mutations_in_twin_breast_cancers

  The aim of this study is to investigate the somatic mutations in twins with BRCA1/2 negative breast cancer with no strong family history.

  Study EGAS00001002379

• Neoantigen-Targeted CD8+ T-Cell Responses 1 With PD-1 Blockade Therapy

  Background: The primary target of T-cell responses induced against cancer cells are peptides derived from non-synonymous mutations presented by HLA (neoantigens). However, the large diversity of HLA alleles and restricted availability of clinical samples have limited the study of the specificity and the evolution over time of the neoantigen-specific T cell responses induced after treatment with immune checkpoint blockade (ICB) immunotherapy. Methods: We applied a newly developed neoepitope-specific T cell isolation technology to perform a longitudinal landscape analysis of the neoepitope-specific T cells in peripheral blood and tumor from 11 patients with metastatic melanoma; 7 with response and 4 with no response to ICB. Briefly, first using computational prediction, the putative neoantigens in each patient were ranked based on affinity for the patient's HLA and expression levels. Then hundreds of barcoded capture reagents consisting of the patient HLA class I subtypes loaded with the corresponding predicted neoantigen were made and used to isolate neoepitope-specific T cells. Once isolated, the TCRs and the barcodes were sequenced. Finally, the tumor reactivity of the isolated neoepitope-specific TCRs (neoTCRs) was assessed upon co-culture of autologous melanoma cell lines from each patient with primary human T cells expressing the neoTCRs generated using a CRISPR-based non-viral gene editing to replace the endogenous TCRs. Results: The tumor mutation burden ranged between 3507 and 177 for patients with response to therapy and 977 to 31 for patients without response to therapy. We screened a median of 172 predicted neoantigen-HLA per patient across their 6 HLA molecules and isolated neoTCRs in all 11 patients. The number of mutations targeted ranged between 13 and 1. We assessed the neoTCR-tumor reactivity in samples from 3 patients with response and 3 patients without response. 39 of the 62 neoTCRs demonstrated specific recognition and cytotoxicity to patient-matched melanoma cell lines. Multiple T cell clonotypes recognized a limited number of mutations in 7 patients with response (median of 41 different neoTCR clonotypes per patient), and the T cell specificities were recurrently detected in the blood and the tumor over time. Samples from 4 patients without response to therapy also demonstrated neoepitope-specific T cell responses in blood and tumor to a similarly restricted number of mutations, but lacked TCR polyclonality (median 6.5 neoTCR clonotypes per patient) and were not recurrently detected in sequential samples. Conclusion: Effective ICB therapy is associated with polyclonal neoepitope-specific T-cell responses in the tumor and blood that recognize a limited number of immunodominant mutations and are recurrently detected over time.

  Study phs003153

• Proteogenomic discovery of a novel class of cancer antigens by HLA ligandome analysis of colon cancer tissues

  CD8+ T cells recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring pathological conditions such as cancer. Recent advances in proteogenomic analysis of HLA ligandomes have demonstrated that cells present a subset of cryptic peptides derived from non-coding regions of the genome; however, the roles of cryptic HLA ligands in tumor immunity remain unknown. In the present study, we comprehensively and quantitatively investigated the HLA class I ligandome of a set of human colorectal cancer (CRC) and matched normal tissues, showing that cryptic translation products account for a small fraction of the HLA class I ligandome and serve as antigens for patient T cell surveillance against colon cancer.

  Study JGAS000280

• Division of Cancer Genomics, National Cancer Center Research Institute Data Access Committee

  Dac EGAC00001000957

• Transcriptome profiling by array

  Expression profiling by Nanostring cancer immune

  Dataset EGAD00010001274

• Bone metastatic biopsies of breast cancer patients progressing on endocrine therapies.

  Study EGAS00001004268

• Detailed molecular and immune marker profiling of archival prostate cancer samples

  Study EGAS00001004396

• Tumour evolvability metrics predict recurrence in advanced localised prostate cancer (tumour data)

  Study EGAS00001006096

• Tumour evolvability metrics predict recurrence in advanced localised prostate cancer (normal data)

  Study EGAS00001006098

• HPV-associated Cancer Consortium Data Access Committee

  HPV-associated Cancer Consortium Data Access Committee

  Dac EGAC50000000088

• Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

  Study EGAS00001006648

• Stabilising selection causes grossly altered but stable karyotypes in metastatic colorectal cancer

  Study EGAS00001004219

• Cancer Alliance Exome

  Exome sequencing for individualized cancer interpretation

  Dataset EGAD00001006236

• EGAD00010000634

  WTCCC2 People of the British Isles (POBI) samples using Affymetrix 6.0 array

  Dataset EGAD00010000634

• Oncotrack_450K_tumor

  Oncotrack primary tumor samples using 450K. The dataset includes shared AF analysis files oncotrackDNAmAnalysis.R and oncotrackDNAmBetaScores.txt which were applied for both Oncotrack_450K_tumor (EGAD00010001162) and Oncotrack_450K_metastatic (EGAD00010001161) datasets.

  Dataset EGAD00010001162

• Whole Genome Sequencing of tissues

  Whole genome sequencing profiling of 4 primary PDAC tissue samples - WGS unmapped reads, sequenced using NovaSeq 6000, 15x coverage 160 million reads per sample.

  Dataset EGAD50000000279

• AVENIO mutation analysis

  Mutation analysis in cfDNA from plasma and urine (stored under different storage conditions) from CRC patients using the AVENIO Expanded Kit

  Dataset EGAD50000001588

• Somatic SNVs and Indels for INSPIRE Tumor WES

  Somatic SNVs and Indels for INSPIRE Tumor WES called using Mutect, Mutect2, Varscan2, Vardict, and Strelka2

  Dataset EGAD00001006569

• Amplicon sequencing

  Fastq files from amplicon sequencing in 106 Multiple Sclerosis patients and 105 healthy volunteers in CD4 T cells, CD8 T cells and genomic DNA using PE300 Illumina MiSeq.

  Dataset EGAD00001005774

• Hi-C datasets of primary glioblastoma cultures

  High-resolution (Sub-5 kbp resolution) Hi-C datasets generated using glioblastoma primary cultures from 3 different adult patients.

  Dataset EGAD00001004968

• Targeted sequencing of head and neck squamous cell carcinomas

  This dataset includes 112 head and neck tumour samples with matched normal (blood) samples sequenced using a custom hybrid capture panel.

  Dataset EGAD00001004269